OS Therapies Q3 10-Q: Going Concern on $431,816 Cash, $30.3M Nine-Month Loss
OSTX is trading near its 52-week low of $0.58 (13% above the low).
Summary
OS Therapies reported a $30.3 million nine-month net loss and $431,816 of cash at September 30, 2026, with management citing substantial doubt about going concern and disclosing that its disclosure controls are not effective.
Key Events · Earnings and Guidance · OSTX
-
Going Concern on Thin Cash
Cash and equivalents stood at $431,816 at September 30, 2026; management states the balance is insufficient to fund operations for at least 12 months, raising substantial doubt about going concern.
-
Nine-Month Loss Widens to $30.3M
The net loss was $30.3 million for the nine months ended September 30, 2026 versus $15.3 million a year earlier, driven by R&D of $19.4 million; accumulated deficit reached $97.5 million.
-
Payables Include $15.0M Biolacuna
Accounts payable and accrued expenses totaled $20.7 million, including approximately $15.0 million owed to advisory firm Biolacuna and $1.4 million accrued for the arbitration award.
-
Controls Deemed Not Effective
Management concluded disclosure controls and procedures were not effective at September 30, 2026 due to inadequate segregation of duties and insufficient personnel with U.S. GAAP experience.
Analysis · OSTX · Life Sciences
With $431,816 of cash at September 30, 2026, a $30.3 million nine-month net loss and $20.7 million of payables, management states plainly that current cash is insufficient to fund operations for at least 12 months — substantial doubt about going concern. Disclosure controls and procedures were also concluded not effective, owing to inadequate segregation of duties and too few staff with U.S. GAAP experience. Funding has come through serial dilutive deals: a $5.0 million secured note tranche in August, a $6.6 million net warrant inducement in October, and a new $75 million at-the-market program with Jefferies. The clinical story remains intact — a BLA submission is planned for Q4 2026 — but the balance sheet, not the science, will determine whether holders get there without further heavy dilution.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OSTX was trading at $0.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $35.6M. The 52-week trading range was $0.58 to $2.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.